Lupin receives approval from USFDA for Bromfenac Ophthalmic Solution
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
The Product will be manufactured at the company's facility in Bengaluru
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Subscribe To Our Newsletter & Stay Updated